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Primary aldosteronism is a frequent form of secondary hypertension that had long been considered relatively benign. Experimental
and clinical evidence collected in the last two decades, however, has clearly demonstrated that this endocrine disorder is associated
with excess cardiovascular and renal complications as compared to essential hypertension. These complications reflect the ability
of inappropriate elevation of plasma aldosterone to cause tissue damage beyond that induced by high blood pressure itself, thereby
setting the stage for major cardiovascular and renal disease. Because of the impact of elevated aldosterone on organ damage, goals
of treatment in patients with primary aldosteronism should not be limited to normalization of blood pressure, and prevention or
correction of organ complications ismandatory. Treatmentwithmineralocorticoid receptor antagonists or unilateral adrenalectomy
is the respective options for treatment of idiopathic adrenal hyperplasia or aldosterone-producing adenoma. Last years have
witnessed a rapid growth in knowledge concerning the effects of these treatments on cardiovascular and renal protection.This paper
is an overview of the cardiovascular and renal complications that occur in patients with primary aldosteronism and a summary of
the results that have been obtained in the long term on cardiovascular and renal outcomes with eithermedical or surgical treatment.
1. Introduction
Aldosterone is secreted by the outermost portion of the
adrenal cortex and contributes to regulation of blood pres-
sure. Aldosterone acts at the distal tubular site of the nephron
where it increases water and sodium reabsorption thereby
leading to extracellular fluid expansion. Evidence collected
in the last two decades indicates that, in addition to the
regulatory role in body fluid and electrolyte balance, aldos-
terone affects a variety of cell functions that may result in
tissue fibrosis. Expression of mineralocorticoid receptors has
been detected in different cell types obtained from cardiac
and vascular tissues [1] and robust experimental evidence
indicates that prolonged exposure to inappropriately elevated
concentrations of aldosterone causes cardiac and renal dam-
age independent of blood pressure levels [2].
Primary aldosteronism (PA) is one of the most frequent
forms of secondary hypertension and among patients with
high blood pressure there is evidence of a much higher
prevalence of this condition than the previously estimated
frequency of less than one percent [3–5]. Hypertension
due to primary aldosteronism had long been considered a
form of disease associated with a relatively low incidence of
cardiovascular and renal complications [6, 7]. This could be
explained by the suppression of renin activity and the related
decrease of angiotensin II formation [8]. More recent views,
however, indicate that a variety of cardiovascular and renal
sequelae that are not merely due to elevated blood pressure
are associatedwith PAandmake this condition far frombeing
benign [9].
Idiopathic adrenal hyperplasia (IHA) and aldosterone
secreting adrenal adenoma (APA) account formore than 95%
of forms of PA and, with few exceptions, are characterized,
respectively, by bilateral or unilateral involvement of the
adrenal glands [10]. Administration of mineralocorticoid
receptor (MR) antagonists or unilateral adrenalectomy is the
respective options for treatment, as indicated in consensus
documents [11]. Both treatments are effective in reducing
blood pressure, although in a relevant proportion of patients
using antihypertensive drugs is needed after treatment to
obtain blood pressure normalization [12]. Moreover, because
of the impact of elevated aldosterone on organ damage,
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goals of treatment in patients with PA should not be limited
to normalization of blood pressure and hypokalemia and
prevention or correction of organ complications becomes
mandatory. In fact, substantial evidence obtained in recent
years indicates that cardiovascular and renal outcomes of
patients with PA do benefit from both MR antagonists and
surgical treatment, although the relative efficacy of these
treatments in the long term remains under debate [13].
This issue will need further investigation because reversal
of aldosterone-related tissue damage is the main factor that
could justify the efforts and expenses of procedures that are
used to differentiate unilateral or bilateral adrenal disease.
Ongoing debate has been generated upon this subject due
to different views of some opinion leaders who claim the
opportunity for search of lateralized aldosterone secretion by
adrenal venous sampling in all PA patients [14, 15] and others
who would limit this procedure to selected groups of patients
[16, 17].
The last few years have witnessed an explosive growth
in knowledge of the genetic basis of PA, and many different
somatic mutations, all involving genes encoding ion chan-
nels, have been described in patients with APAs [18]. After
the first seminal report of Choi et al. [19] in which two
different mutations (G151R and L168R) were identified in Kir
3.4 (KCNJ5), an inwardly rectifying potassium channel, other
somatic mutations of the alpha-subunit of Na+/K+ ATPase
(ATP1A1) [20], Ca2+ ATPase calcium channel (ATP2B3) [21],
and voltage-gated calcium channel (CACNA1D) [22] have
been demonstrated in APAs removed from PA patients.Their
relative prevalence has subsequently been characterized in
patients with PA of different ethnicity [23, 24]. Detection
of these mutations has been associated with some features
of patients with PA including more severe aldosterone over-
production [19, 24] or reduced responsiveness of plasma
aldosterone to postural changes [23]. Therefore, it might be
possible that patients with APAs carryingmutated genes have
worse responses to treatments and possibly a greater burden
of cardiovascular and renal complications, both issues that
start being investigated in specifically designed studies [25].
This paper is an overview of the cardiovascular and renal
complications that occur in patients with PA and a summary
of the results that have been obtained in the long term on
cardiovascular and renal outcomes with either medical or
surgical treatment.
2. Cardiovascular Outcomes
As stated previously, current treatment for APA is adrenalec-
tomy, because surgery apparently confers a greater possibility
of cure and avoids the possible side effects of MR antagonists
[26]. Chronic administration of these agents, however, is the
treatment of choice in IHA. Although primary aldosteronism
is considered correctable, in many cases, hypertension may
persist after treatment [27–29]. Most studies on the effects of
treatment of primary aldosteronism on blood pressure have
been conducted in patients with APA, and a cumulative anal-
ysis of initial case series indicated a rate of hypertension cure
of 59% following adrenalectomy [30]. In most of these series,
however, cure was defined by reaching a blood pressure of
less than 160/100mmHg. Subsequent evidence has indicated
that only approximately one third of patients treated for PA
reach a blood pressure of less than 140/90mmHg without
the use of additional antihypertensive drugs [5, 30, 31]. These
estimates were obtained in retrospective investigations and
are in full agreement with the results of a prospective study of
PA patients with either IHA or APA, 39% of whom had their
blood pressure normalized by spironolactone or adrenalec-
tomy, respectively, while in the remaining 61% blood pressure
levels fell by more than 20% and fewer antihypertensive
agents were needed to reach values below 140/90mmHg [28].
Initial studies reported a low prevalence of cardiac com-
plications in patients with PA [6] and subsequent cross-
sectional assessments yielded evidence of a prevalence of
such complications comprised of 14% to 35% [4, 32, 33].
Most of these prevalence studies, however, had important
limitations due to lack of appropriate control subjects. In
a first longitudinal retrospective study [34], a significantly
increased rate of cardiovascular events was reported in
patients with PA as compared to patients with essential
hypertension (EH). The study reported a striking increase
in the relative risk of myocardial infarction (6.5), atrial
fibrillation (12.1), and stroke (4.2). We conducted a study [35]
in 54 patients with PA and 323 patients with EH who were
accurately matched for age, gender, severity and estimated
duration of hypertension, and cardiovascular risk scores.
Comparisons revealed a greater prevalence of cardiovascular
disease in patients with PA than in those with EH, with
an odds ratio of 2.80, 4.93, and 4.36 for coronary heart
disease, sustained arrhythmia (mostly atrial fibrillation), and
cerebrovascular events, respectively. In this study, prevalence
of cardiovascular complications was comparable in patients
with idiopathic or tumoral adrenal disease, showing that both
subtypes of PA are at increased risk. In the cohort of the
German Conn’s registry [36], prevalence of coronary heart
disease was 16.3%, and that of atrial fibrillation and ventric-
ular arrhythmias was 7.1% and 5.2%, respectively. Although
this survey did not have a control group, prevalence of cardiac
events in patients with PA was much higher than that of
registry patientswith EHand comparable cardiovascular risk.
More recently, prevalence of cardiovascular events has been
compared in 459 patients with PA and 1290 matched patients
with EH [37] confirming significantly higher prevalence rates
of myocardial infarction, atrial fibrillation, and heart failure.
Finally, in a longitudinal retrospective comparison of 270
patients with PA with 1 : 3 case-control matched patients
with EH, Mulatero et al. [38] reported a higher rate of
cardiovascular events including stroke and arrhythmia over
a median follow-up of 12 years. Consistent with our previous
findings, these authors reported comparable rate of events in
PA patients with IHA or APA.Thus, findings of all these stud-
ies convincingly demonstrate that elevated aldosterone levels
in PA contribute to cardiovascular damage independent of
blood pressure (Table 1). To further support this conclusion,
prospective evidence has linked, in the long term, treatment
of PA with improvement of cardiovascular outcomes [35].
These outcomes were compared in patients with EH and
patients with PA who had comparable cardiovascular risk
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Table 1: Relative risk of cardiovascular events in patients with
primary aldosteronism versus patients with essential hypertension.
Study Coronaryheart disease
Cerebrovascular
disease
Sustained
arrhythmia
Milliez et al.
2005 [34] 6.5 4.2 12.1
Catena et al.
2008 [35] 2.8 4.4 4.9
Savard et al.
2013 [37] 2.6 — 5.0
Mulatero et al.
2013 [38] 0.9 2.2 2.2
profile but greater retrospective incidence of coronary heart
disease, arrhythmias, and cerebrovascular events. Patients
were followed for an average period of 7.4 years after treat-
ment, duringwhich occurrence of a combined cardiovascular
endpoint was comparable in the two groups. Analysis of
patients with PA treated with MR antagonists or adrenalec-
tomy did not reveal significant differences in cardiovascular
outcome, indicating that medical and surgical treatment are
equally effective in the prevention of cardiovascular events.
In a more recent prospective study, the cardiovascular risk
has been compared in 132 patients with EH and 102 patients
with PA who had worse baseline risk profile and were treated
with either MR antagonists or adrenalectomy [39]. After an
average follow-up of 44months, the cardiovascular risk of PA
patients was significantly reduced and became comparable to
that of patients with EH.
It is known that subclinical cardiac and vascular changes
anticipate major cardiovascular events in patients with high
blood pressure. In patients with PA, higher prevalence of a
variety of cardiac abnormalities has been reported together
with structural [40] and functional [41] vascular changes.
Left ventricular hypertrophy is a strong and independent
risk factor for major cardiac events [42] and cross-sectional
echocardiographic studies reported greater left ventricular
mass and more frequent left ventricular hypertrophy in
patients with PA than patients with other types of hyper-
tension. Moreover, detection of inappropriately elevated left
ventricular mass is increased in PA even in the absence
of left ventricular hypertrophy [43] suggesting that in high
aldosterone states left ventricular mass increases beyond
the amount needed to compensate for the blood pressure
related workload. Also, in PA excess left ventricular mass is
associated with abnormal left ventricular filling suggestive
of diastolic dysfunction and myocardial fibrosis [44]. A
magnetic resonance imaging study demonstrated increased
myocardial fibrosis and ventricular stiffening in 25 patients
with PA as compared to matched normotensive controls [45]
and plasma procollagen levels were found to be higher in
20 patients with APA as compared to patients with EH, a
difference that disappeared after adrenalectomy [46].
Echocardiographic investigations of cardiac changes after
treatment of PA were initially confined to short-term stud-
ies performed after adrenalectomy and showed significant
reduction of the left ventricular mass together with improve-
ment of diastolic function [44]. Later on, data on long-term
effects on cardiac structure and function of both medical and
surgical treatment of PA have been published [47]. In a first
7-year follow-up study, it was demonstrated that PA patients
treated with either spironolactone or adrenalectomy have
significant and comparable decrease in left ventricular mass,
although decrease is significant within the first year only
after surgery [28]. More recently, two studies [48, 49] have
reported a decrease of left ventricular mass both in medically
and surgically treated PA patients, but changes have reached
statistical significance only in the latter group, whereas
another study did not find any change in left ventricular mass
in patients treated with MR antagonists [50]. These studies
have been the subject of a recentmeta-analysis [51] indicating
that the effects on left ventricular mass of medical and
surgical treatment of PA do not differ significantly (Table 2).
Finally, in a multivariate regression analysis of 54 patients
with PA who were followed for 6.4 years after treatment with
spironolactone or adrenalectomy it was reported that the
degree of reduction in left ventricular mass in PA patients
treated both medically and surgically was independently
predicted not only by change in blood pressure but also by
pretreatment plasma aldosterone levels [52].This observation
further supports the hypothesis that aldosterone contributes
to development of left ventricular hypertrophy independent
of the hypertension-related hemodynamic load. Because of
recent advances in understanding the genetic basis of PA,
future efforts will have to address that possible relevance
of somatic mutations detected in APAs for cardiovascular
complications of PA and outcomes of treatment. In a recent
study of 129 patients with APA, Rossi et al. have reported that
plasma aldosterone levels and left ventricular mass are higher
in patients with APA carrying KCNJ5mutations as compared
to patientswithwild-typeAPA [25].However, in this study no
differences in left ventricular mass reduction were observed
after adrenalectomy in patients with mutated or wild-type
APA.
High-affinity MR has been detected in cardiac myocytes
and fibroblasts [1] and their activation has been shown
to induce myocardial damage independent of blood pres-
sure elevation [2]. Animal experiments demonstrated that
aldosterone infusion causes myocardial fibrosis in rats that
are fed a high-salt containing diet [53]. In these animals,
fibrosis is preceded by inflammation of the perivascular
tissue [54] and both myocardial inflammation and fibrosis
can effectively be prevented by either removal of adrenal
glands or administration of MR antagonists [55]. Activation
of MR might therefore cause myocardial changes and the
related cardiac dysfunction through a variety of mechanisms
including activation of oxidative stress [56, 57]. In fact, the
beneficial effects on myocardial fibrosis of MR antagonists
[58] have been associated with decreased generation of reac-
tive oxygen species in cardiomyocytes [59] and additional
evidence of an involvement of mechanisms that are tightly
related to induction of oxidative stress has been obtained in
geneticallymanipulated animals [60, 61]. Interruption ofMR-
mediated mechanisms might explain why, in the long term,
treatment of primary aldosteronismwithMR antagonists has
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Table 2: Summary of results obtained in studies that evaluated the long-term response of left ventricular mass to either medical treatment
or surgical treatment in primary aldosteronism.
Study Follow-up years Medical treatment Surgical treatment
Baseline End of study Baseline End of study
Catena et al.,
2007 [28] 6.4 52 ± 2 44 ± 2
† 53 ± 2 43 ± 2∗
Giacchetti et al.∗
2007 [49] 3.7 135 ± 4 125 ± 7 126 ± 5 116 ± 5
∗
Bernini et al.,
2012 [50] 2.7 65 ± 2 65 ± 3 58 ± 2 49 ± 3
∗
Rossi et al.,
2013 [48] 3.0 50 ± 1 47 ± 1 53 ± 1 49 ± 1
∗
Values of left ventricular mass index are expressed as g/m2.7 except for the study of Giacchetti et al. (∗) that expressed as left ventricular mass (g). †𝑃 < 0.05
versus baseline.
Data in the table have been included in a meta-analysis [51] showing that effects of medical and surgical treatment of primary aldosteronism on left ventricular
mass are not significantly different.
comparable effects to the removal of APA in reducing left
ventricular mass although this response occurs later than
removal of excess circulating aldosterone by adrenalectomy.
Persistent hyperaldosteronemia with possible involvement
of nongenomic effects of aldosterone [62] might possibly
explain the difference in response to medical or surgical
treatment.
MRs are found in epithelial and nonepithelial tissues
with high affinity for aldosterone and glucocorticoid hor-
mones. Under physiological conditions, the majority of MRs
in nonepithelial tissues are bound to cortisol, whereas in
epithelial tissues, binding of cortisol to MR is prevented by
11𝛽-hydroxysteroid dehydrogenase (11𝛽-HSD2), the enzyme
that converts cortisol to the receptor-inactive cortisone.
Moreover, activity of 11𝛽-HSD2 generates NADH from NAD
and produces changes in the intracellular redox potential that
might, in turn, inactivate the glucocorticoid-MR complex
[63]. 11𝛽-HSD2 is not present in nonepithelial tissues includ-
ing the heart, but in such tissues, changes of the intracellular
redox potential can result from generation of reactive oxygen
species and thereby affect the activity of the MR [63]. In
vitro experiments have demonstrated that changes in the
redox potential of cardiomyocytes by exposure to oxidized
glutathione turn cortisol from being an MR antagonist to an
agonist [64]. Recently, it has been shown that aldosterone
itself induces changes in the intracellular redox potential in
different cell types [65] through an activation of the NOX1
catalytic subunit of NAD(P)H oxidase. This aldosterone-
dependent change in the redox potential is amplified by
exposure to high concentrations of salt [65] leading to
increased production of reactive oxygen species and thereby
to cellular and tissue injury.
3. Renal Outcomes
Although animal studies demonstrated that inappropriately
elevated aldosterone levels for the salt status cause renal tissue
damage [66], the clinical evidence of a role of aldosterone as a
potential contributor to renal dysfunction is weaker than that
emerged for the cardiovascular system [67]. Indirect evidence
of untoward renal effects of aldosterone came from demon-
stration of benefits obtained with use of MR antagonists in
patients with proteinuric disease due to diabetes [68] or other
types of renal disease [69]. Cross-sectional studies of renal
function in PA have reported high variability in prevalence
of renal damage [32]. Initial studies with kidney biopsies
demonstrated only moderate tissue damage in patients with
PA and reported prevalence of impaired renal function in no
more than 7% of patients with this condition [70]. Similarly, a
single-center study has reported 24-hour creatinine clearance
of less than 60mL/min/1.73m2 in only 7% of 56 patients with
PA [71], whereas in the German Conn’s Registry increased
plasma creatinine concentration was found in a substantially
higher percentage of patients [72]. In patients with PA
prevalence of overt proteinuria varied from 8% [60] to 24%
[70] a disparity that could be explained by differences in
severity and duration of hypertension. In a large, multicenter,
Italian study [73], prevalence ofmicroalbuminuria in patients
with PA was twofold that of patients with EH.
Crucial data on the role of the kidney in PA were
reported in two prospective studies in which PA patients
were followed in the short and long term after treatment.
In 25 patients with adrenal adenoma who were followed for
6 months after adrenalectomy, Ribstein et al. [74] found a
significant decrease in urinary protein excretion that was
associated with a significant decrease in glomerular filtration.
In a 9-year follow-up study of patients with either IHA
or APA, we demonstrated that microalbuminuria is more
likely to subside to normal levels after treatment than to
progress to overt proteinuria [75]. In this study, normal-
ization of urinary protein excretion was more frequent in
patients with PA than in matched patients with EH and
this effect was independent of blood pressure changes. Renal
outcomes were assessed by measuring the rates of change
of glomerular filtration rate and urinary protein excretion.
After an initial fall in creatinine clearance observed in
patients with PA, subsequent declines in glomerular fil-
tration in patients with PA (−1.15mL/min/1.73m2/year) or
EH (−1.06mL/min/1.73m2/year) were comparable. Urinary
albumin losses did not differ between patients with PA or EH
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during the long-term phase of follow-up. Separate analysis of
renal outcomes in patients with PA who were treated with
spironolactone or adrenalectomy did not reveal significant
differences.
These two important prospective studies have consis-
tently indicated that PA is characterized by a partially
reversible renal dysfunction, suggesting that proteinuria
might be the marker of a renal hemodynamic defect. Con-
sistent with the findings of past investigations conducted on
the effects of mineralocorticoid hormones on renal function
[76] some of which in experimental animals with use of the
renal micropuncture technique [77], these two studies have
demonstrated the presence of relative glomerular hyperfil-
tration in patients with PA as compared with appropriately
matched patients with EH. The analysis of the patients
included in the German Conn’s Registry [72] has confirmed
that glomerular filtration falls rapidly after treatment of PA
and remains relatively stable thereafter. Also andmost impor-
tantly, evaluation of intrarenal Doppler velocimetric indexes
has demonstrated significantly lower intrarenal vascular
resistance in patients with PA as compared to patients with
EH and reversal of this abnormal intrarenal hemodynamic
pattern one year after treatment [78]. In summary, findings
of longitudinal studies consistently demonstrate that the
hallmark of renal dysfunction in PA is reversible glomerular
hyperfiltration that is caused by reduced intrarenal vascular
resistance and increases urinary protein excretion. The fre-
quency of regression ofmicroalbuminuria in PA suggests that
urinary albumin excretion is, at least in part, a marker of
functional rather than structural renal changes. On the other
hand, long-term persistence of albuminuria in a substantial
proportion of patients with PA is associated with detectable
baseline plasma renin levels [27, 71] suggesting coexistence
of structural intrarenal vascular damage presumably due to
long-standing hypertension prior to treatment.
Similar to the heart, exposure to aldosterone levels that
are inappropriate for the salt status or activation of MR can
damage the kidney via mechanisms that are independent of
blood pressure [2]. Elevated aldosterone produces intrarenal
vascular injury, glomerular damage, and tubulointerstitial
fibrosis in the kidney of stroke-prone spontaneously hyper-
tensive [79] and uninephrectomized rats [80]. Because of
the relationship between aldosterone-related tissue damage
and salt intake, it was suggested that effects of high-salt
intake could be dependent on activation of MR and that
this activation might reflect increased oxidative stress [81].
In fact, infusion of aldosterone in the presence of high-salt
diet increases the expression of the renal nicotinamide ade-
nine dinucleotide phosphate [NAD(P)H]-oxidase 4 (NOX4),
increasing the generation of reactive oxygen species in the
kidney. In these high-salt fed animals, administration of
MR antagonists or NAD(P)H-oxidase inhibitors prevents
aldosterone-induced increase in blood pressure and reduc-
tion of plasma nitric oxide levels and decreases urinary
markers of oxidative stress [82]. In summary, in addition to
thewell-known effects of salt excess on vascular stiffening and
blood pressure increase, some effects of salt loading might
depend on MR activation reflecting increased oxidative
stress.
Another issue that is worth mentioning is related to
prevalence of simple renal cysts in PA. In a first cross-
sectional study, Torres et al. [83] used CT scans to assess
presence, number, and total volume of simple cysts in kidneys
of patients with PA in comparison to EH. Renal cysts were
present in 24 of 55 patients with PA with a prevalence of
44% versus a prevalence of 25% in age-matched patients with
EH. Also, in this study a higher overall renal cysts number
and volume were found in patients with PA. In other studies
without appropriate control groups, prevalence of renal cysts
in patients with PA varied from 16% to 26% [27, 84, 85]
depending upon differences in age, sex distribution, duration
of hypertension, severity of hypokalemia, and methods used
to detect cysts. In a prospective study, we have examined
the prevalence of renal cysts in a group of patients with PA
who were reassessed after a median follow-up of 6.2 years
[86]. At baseline, patients with PA (both IHA and APA)
were compared with age and sex-matched patients with EH
and normotensive controls.The prevalence of renal cysts was
significantly greater in patientswith PA (37%) than in patients
with EH (18%) and normotensive controls (12%) as well as
the average number of renal cysts per patient (1.11, 0.51, and
0.25, resp.). Also andmost importantly, development of renal
cysts subsided after medical or surgical treatment of PA and
no significant change of cyst number and cyst total volume
from baseline was found at the end of study in both IHA and
APA. Thus, renal cystic disease is highly prevalent in PA and
treatment halts its progression, supporting the contention
that persistent hypokalemia is the causative factor.
4. Conclusions
Current evidence unquestionably indicates a high rate of
cardiovascular complications in patients with PA, showing
that this condition is far from being benign. The high rate
of complications in PA patients, however, is not merely
explained by blood pressure elevation. Elevated aldosterone
causesmyocardial hypertrophy and fibrosis over that induced
by high blood pressure itself and, together with vascular
structural and functional changes, sets the stage for future
cardiovascular events. With regard to the kidney, there
are PA intrarenal hemodynamic changes leading to relative
glomerular hyperfiltration and increased urinary protein
losses. These functional changes are fully reversible until
structural damage of intrarenal vessels ensues as the result of
persistent hypertensive insult. Follow-up studies of patients
with PA indicate that both medical and surgical treatments
effectively lower blood pressure, correct subclinical organ
damage, and decrease the risk of cardiovascular events and
renal disease progression. In this view, timely identification of
PA patients becomes mandatory to effectively prevent organ
complications. Althoughduring the last yearsmany questions
related to the effects of aldosterone on the cardiovascular and
renal system have been satisfactorily answered, many others
still await clarification.
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